[Treatment of cardiac failure with enalapril]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Cardiac failure leads to reduced cardiac output, activating the renin-angiotensin-aldosterone system.
• This activation causes arteriolar constriction, worsening cardiac output and myocardial damage.

Purpose of the Study:

• To evaluate the efficacy of enalapril, an angiotensin-converting enzyme inhibitor, in treating severe cardiac failure.
• To assess the impact of enalapril on functional symptoms, exercise capacity, and hemodynamic parameters in heart failure patients.

Main Methods:

• A double-blind study involving 36 heart failure patients treated with digitalis and diuretics.
• Patients were randomized to receive either enalapril or a placebo in addition to their existing medications.
• Enalapril was also administered intravenously to 10 patients with acute left ventricular failure post-myocardial infarction.

Main Results:

• Two-thirds of patients receiving enalapril showed improvements in functional symptoms, exercise tests, left ventricular function, and hemodynamics.
• No improvements were observed in the placebo group.
• Intravenous enalapril in acute left ventricular failure patients resulted in a significant reduction in pulmonary capillary pressure and systemic arterial resistance within one hour.

Conclusions:

• Enalapril is an effective treatment for severe cardiac failure, addressing a critical pathophysiological mechanism.
• The drug demonstrates significant benefits in improving cardiac function and reducing adverse hemodynamic effects in heart failure patients.